Keywords
Cardiac complications
Early diagnosis
Antiparasitic therapy
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objectives: Critically analyze the evidence available in the scientific literature on diagnosis, treatment and cardiac complications associated with Chagas disease, highlighting current therapeutic perspectives. Methods: This is an integrative review, carried out from the selection of 09 studies indexed in the databases PubMed, Lilacs and Scielo, between the years 2014 to 2024. Descriptors such as "Chagas disease", "Trypanosoma cruzi", "diagnosis" and other related terms were used with Boolean operators in publications in Portuguese, Spanish and English. Results: The selected studies showed important advances in the diagnostic and therapeutic field, highlighting the need to update clinical guidelines and the search for new management strategies, such as the use of experimental therapies, improvements in the early detection and strengthening of public policies aimed at controlling the disease. Final considerations: The analysis of the literature has shown that, despite the progress achieved, there are still significant gaps in the early diagnosis and effective treatment of Chagas disease, especially in chronic forms. The social relevance of the study is reflected in the need to expand access to diagnosis and treatment, with a direct impact on patients' quality of life and reduction of morbidity and mortality associated with the disease.
References
ALVARENGA AMERICANO DO BRASIL PE, et al. Selenium Treatment and Chagasic Cardiopathy (STCC): study protocol for a double-blind randomized controlled trial. Trials. 2014;15:388.
ANDRADE JP, et al. I Latin American guidelines for the diagnosis and treatment of Chagas’ heart disease: executive summary. Arq Bras Cardiol. 2011;96(6):434-42.
BERN C. Chagas’ disease. N Engl J Med. 2015;373(5):456–466.
BONNEY KM, ENGMAN DM. Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead. Am J Pathol. 2015;185(6):1537–1547.
BRITO BOF. A evolução do eletrocardiograma na doença de Chagas: usos no diagnóstico, prognóstico e no seguimento de idosos [tese]. Belo Horizonte: Universidade Federal de Minas Gerais, Faculdade de Medicina; 2022.
BRAVO-TOBAR R, et al. Serum activity of adenosine deaminase, C-reactive protein levels and clinical profile in chronic Chagas disease patients. Rev Inst Med Trop Sao Paulo. 2015;57(6):505-12.
CHUIT R, et al. Diagnosis and management of chagasic cardiomyopathy patients in several institutions in Argentina. Front Parasitol. 2023;2:1195646.
COLANTONIO LD, et al. Electrocardiographic abnormalities and treatment with benznidazole among children with chronic infection by Trypanosoma cruzi: a retrospective cohort study. PLoS Negl Trop Dis. 2016;10(5):e0004651.
DIAS JCP, et al. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz. 2016;111(6):407–419.
FERREIRA JM Jr, et al. Chagas cardiomyopathy: therapeutic use of benznidazole and clinical evolution in endemic regions of Brazil. Rev Soc Bras Med Trop. 2016;49(2):184-9.
HOCHBERG NS, MONTGOMERY SP. Chagas Disease. Ann Intern Med. 2023;176(2):ITC17–ITC32.
KELLY EA, et al. Comparative performance of latest-generation and FDA-cleared serology tests for the diagnosis of Chagas disease. J Clin Microbiol. 2021;59(6):e00158-21.
LIMA MM, et al. Left ventricular mechanics in Chagas disease studied by speckle tracking echocardiography. Echocardiography. 2016;33(5):690-7.
MARIN-NETO JA, et al. Diretriz da SBC sobre Diagnóstico e Tratamento de Pacientes com Cardiomiopatia da Doença de Chagas – 2023. Arq Bras Cardiol. 2023;120(6):e20230269.
MAZZETI AL, et al. Review on Experimental Treatment Strategies Against Trypanosoma cruzi. J Exp Pharmacol. 2021;13:409–432.
MEDEIROS CA, et al. Mapping the morbidity and mortality of Chagas disease in an endemic area in Brazil. Rev Inst Med Trop Sao Paulo. 2022;64.
MENDES FDSNS, et al. Effect of physical exercise training in patients with Chagas heart disease: study protocol for a randomized controlled trial (PEACH study). Trials. 2016;17:433.
MORILLO CA, et al. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. N Engl J Med. 2015;373(14):1295–1306.
NGUYEN T, WASEEM M. Chagas Disease (American Trypanosomiasis). Treasure Island (FL): StatPearls Publishing; 2020.
NUNES MCP, et al. Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation. 2018;138(12):e169–e209.
PÉREZ-MOLINA JA, MOLINA I. Chagas disease. Lancet. 2018;391(10115):82–94.
PINAZO MJ, et al. Immunosuppression and Chagas disease: a management challenge. PLoS Negl Trop Dis. 2017;11(1):e0005280.
RASSI DDC , et al. Echocardiographic parameters and survival in Chagas heart disease with severe systolic dysfunction. Arq Bras Cardiol. 2014;102:245–252.
SEGURA EL, et al. Long-term follow-up of children with chronic Chagas disease treated with benznidazole in Salta, Argentina. Rev Soc Bras Med Trop. 2016;49(2):182–8.
SOARES NM, et al. Seroepidemiological Survey of Chronic Chagas Disease in a Rural Community in Southern Bahia, Brazil, Using Recombinant Chimeric Antigens. Pathogens. 2023;12(10):1222.
VIOTTI R, et al. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother. 2014;58(2):635–9.
VERGARA C, et al. Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox. PLoS One. 2019;14(8):e0221100.